Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739435 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Alumis.
- Active
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT05739435: Active Phase 2 study of Plaque Psoriasis, sponsored by Alumis.
NCT05739435 is a Phase 2 study of Plaque Psoriasis that is active but no longer recruiting, run by Alumis. The registered enrollment target is 165 participants, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05739435, a Phase 2 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Alumis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Conditions Studied
Interventions
- DRUG ESK-001
Study Locations (20)
California
- Investigator Site #1021 - Encinitas
- Investigator Site #1018 - Los Angeles
- Investigator Site #1007 - Santa Monica
- Investigator Site #1002 - Sherman Oaks
Florida
- Investigator site # 1030 - Fort Lauderdale
- Investigator Site #1025 - Hialeah
- Investigator site # 1028 - Miami
- Investigator Site # 1013 - Tampa
Georgia
- Investigator Site #1035 - Macon
- Investigator Site #1043 - Sandy Springs
Indiana
- Investigator Site # 1011 - Columbus
- Investigator Site #1027 - South Bend
Alabama
- Investigator Site # 1029 - Birmingham
Arizona
- Investigator Site #1001 - Phoenix
Arkansas
- Investigator Site # 1023 - Rogers
Illinois
- Investigator Site #1005 - Rolling Meadows
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
What the registry record for NCT05739435 still lists
NCT05739435 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ESK-001 is the first listed.
NCT05739435 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05739435 about?
NCT05739435 is a clinical study titled "Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis". This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
What is the current status of trial NCT05739435?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2023-01-17. Estimated completion is 2026-12-30.
What conditions does trial NCT05739435 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05739435?
The interventions under investigation include: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT05739435?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739435 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05739435's enrollment target sits among peer trials
165 23rd of 45 higher than 23 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI